MGUS and Smoldering Myeloma | Memorial Sloan Kettering

Serum biomarkers as predictors of disease progression in smoldering myelomaПодробнее

Minimal Residual Disease in MyelomaПодробнее

When to Treat Smoldering MyelomaПодробнее

C. Ola Landgren on Treating Smoldering Multiple MyelomaПодробнее

Who is High-risk smoldering myeloma | Dr. S. Vincent RajkumarПодробнее

Myeloma Canada InfoVideo Series #31 - MGUS and Smoldering Multiple MyelomaПодробнее

Study on Risk Stratification in Smoldering Myeloma Patients | Malin Hultcrantz, MD, PhD | IMS 2023Подробнее

Changing perceptions of MGUS progression: explaining the dataПодробнее

Molecular Profiling for Myeloma and Its Precursor DiseaseПодробнее

Diagnosing and Treating Smoldering Multiple MyelomaПодробнее

iStopMM Trial - Covid Vaccine and Impact on Myeloma | Malin Hultcrantz, MD, PhD | ASH 2022Подробнее

Lymphoma Services | Memorial Sloan Kettering Cancer CenterПодробнее

Myeloma Crowd: David Chung, MD, PhD, Memorial Sloan Kettering Cancer CenterПодробнее

Understanding MGUS, Smoldering and Multiple MyelomaПодробнее

Basics of MGUS and Smoldering Myeloma - Shaji Kumar, MD | MCRT Webcast September 26 (1/3)Подробнее

Immunotherapy: How It WorksПодробнее

Myeloma Crowd Radio: Alexander Lesokhin, MD, Memorial Sloan Kettering CCПодробнее

African American SMM Patients may have Lower Risk of Progression Compared to White SMM PatientsПодробнее

MCRT Phoenix 2017: MGUS and Smoldering Myeloma by Shaji Kumar, MDПодробнее

Can diet impact treatment outcomes and progression of patients with multiple myeloma?Подробнее